RhoVac AB announced the appointment of oncology expert to its Scientific Advisory Board with the addition of Anne J. Ridley, PhD, Professor of Cell Biology and Head of School of Cellular and Molecular Medicine, University of Bristol, UK. Professor Ridley will serve as a strategic advisor to RhoVac as the company continues the RV001 project. Professor Ridley, PhD, joins RhoVac Scientific Advisory Board with 30 years of research experience in cancer. Her research has made major contributions to the understanding of cancer, tumour progression and inflammation through her work on cell migration and the Rho family of GTPases, of which RhoC is key to RhoVac. After being awarded with a Doctor of Philosophy degree from University of London in 1989, she proceeded her postdoctoral research at the Whitehead Institute in Cambridge, Massachusetts, USA, and at the Institute of Cancer Research in London, UK. Ridley was appointed research group leader at the Ludwig Institute for Cancer Research at University College London (UCL) from 1993 to 2007 and Professor of Cell Biology at UCL from 2003 to 2007, then at King’s College London from 2010-1017. In 2017, Professor Ridley was elected a Fellow of the Royal Society (FRS). In 2018 she was appointed Professor of Cell Biology at the University of Bristol and Head of School of Cellular and Molecular Medicine.